The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
Open Access
- 17 February 2022
- Vol. 10 (2), 320
- https://doi.org/10.3390/vaccines10020320
Abstract
Two mRNA COVID-19 vaccines (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) and one viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) are authorized in the US to hinder COVID-19 infections. We analyzed severe and common adverse events in response to COVID-19 vaccines using real-world, Vaccine Adverse Effect Reporting System (VAERS) data. From 14 December 2020 to 30 September 2021, 481,172 (50.7 ± 17.5 years, males 27.89%, 12.35 per 100,000 people) individuals reported adverse events (AEs). The median time to severe AEs was 2 days after injection. The risk of severe AEs following the one viral vector vaccine (OR = 1.044, 95% CI = 1.005–1.086) was significantly higher than that after the two mRNA vaccines, and the risk among males (OR = 1.374, 95% CI = 1.342–1.406) was higher than among females, except for anaphylaxis. For common AEs, however, the risk to males (OR = 0.621, 95% CI = 0.612–0.63) was lower than to females. In conclusion, we provided medical insight and clinical guidance about vaccine types by characterizing AEs using real-world data. In particular, COVID-19 mRNA vaccines are safer than viral vector vaccines with regard to coagulation disorders, whereas inflammation-related AEs are lower in the viral vaccine. The risk–benefit ratio of vaccines should be carefully considered, and close monitoring and management of severe AEs is needed.Funding Information
- Ministry of Trade, Industry and Energy (20015086)
- Ministry of Science and ICT (_, 2019-0-00224)
- Ministry of Education (2020R1F1A1068423, NRF-2019M3C7A1032262)
This publication has 25 references indexed in Scilit:
- Surveillance for Adverse Events After COVID-19 mRNA VaccinationJAMA, 2021
- COVID‐19 Vaccine‐Associated Cerebral Venous Thrombosis in GermanyAnnals of Neurology, 2021
- Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental?The American Journal of Case Reports, 2021
- Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccinesVaccine, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Risk of anaphylaxis after vaccination in children and adultsJournal of Allergy and Clinical Immunology, 2015
- Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2015
- Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experienceExpert Review of Vaccines, 2008